NSPR 📈 InspireMD - Overview
Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US45779A8466
NSPR: Stents, Carotid Systems, Stroke Treatment Devices
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. Web URL: https://www.inspiremd.com
Additional Sources for NSPR Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NSPR Stock Overview
| Market Cap in USD | 77m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Supplies |
| IPO / Inception | 2011-04-12 |
NSPR Stock Ratings
| Growth 5y | -66.4% |
| Fundamental | -33.7% |
| Dividend | - |
| Rel. Strength Industry | 405 |
| Analysts | 4/5 |
| Fair Price Momentum | 2.32 USD |
| Fair Price DCF | - |
NSPR Dividends
No Dividends PaidNSPR Growth Ratios
| Growth Correlation 3m | 54.2% |
| Growth Correlation 12m | 16.8% |
| Growth Correlation 5y | -70.1% |
| CAGR 5y | -28.12% |
| CAGR/Mean DD 5y | -0.36 |
| Sharpe Ratio 12m | 0.33 |
| Alpha | -22.29 |
| Beta | 1.10 |
| Volatility | 61.79% |
| Current Volume | 20.4k |
| Average Volume 20d | 33.8k |
What is the price of NSPR stocks?
As of December 28, 2024, the stock is trading at USD 2.87 with a total of 20,378 shares traded.
Over the past week, the price has changed by -3.69%, over one month by -4.97%, over three months by +5.51% and over the past year by +24.24%.
As of December 28, 2024, the stock is trading at USD 2.87 with a total of 20,378 shares traded.
Over the past week, the price has changed by -3.69%, over one month by -4.97%, over three months by +5.51% and over the past year by +24.24%.
Is InspireMD a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, InspireMD (NASDAQ:NSPR) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -33.67 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NSPR as of December 2024 is 2.32. This means that NSPR is currently overvalued and has a potential downside of -19.16%.
Probably not. Based on ValueRay Fundamental Analyses, InspireMD (NASDAQ:NSPR) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -33.67 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NSPR as of December 2024 is 2.32. This means that NSPR is currently overvalued and has a potential downside of -19.16%.
Is NSPR a buy, sell or hold?
InspireMD has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy NSPR.
InspireMD has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy NSPR.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for NSPR stock price target?
According to ValueRays Forecast Model, NSPR InspireMD will be worth about 2.6 in December 2025. The stock is currently trading at 2.87. This means that the stock has a potential downside of -10.1%.
According to ValueRays Forecast Model, NSPR InspireMD will be worth about 2.6 in December 2025. The stock is currently trading at 2.87. This means that the stock has a potential downside of -10.1%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 4.5 | 56.8% |
| Analysts Target Price | 4.4 | 51.6% |
| ValueRay Target Price | 2.6 | -10.1% |